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Introduction
Prostaglandin endoperoxide H synthases (PGHSs 1 )-1 and -2, also called cyclooxygenases (COXs), catalyze the conversion of arachidonic acid (AA) to prostaglandin H 2 (PGH 2 ) in the committed step in prostaglandin and thromboxane biosynthesis (Rouzer and Marnett, 2003 ; Rouzer and Marnett, 2008; Schneider et al., 2007; Smith, 2008; van der Donk et al., 2002) . The enzymes have two catalytic activities: (a) a cyclooxygenase (COX) activity responsible for oxygenating AA to PGG 2 and (b) a peroxidase activity that catalyzes a two electron reduction of PGG 2 to PGH 2 . PGHSs are homodimers that exhibit half of sites COX activity with AA as the substrate (Yuan et al., 2006) . That is, only one monomer is able to catalyze a reaction at a given time. The non-catalytic monomer functions as an allosteric regulator of the catalytic monomer ( Kulmacz and Lands, 1985; Yuan et al., 2006; Yuan et al., 2009) . This is of potential importance in vivo where certain fatty acids can function as allosteric regulators of PGHSs inhibiting PGHS-
and stimulating PGHS-2 (Yuan et al., 2009).
Nonspecific nonsteroidal anti-inflammatory drugs (nsNSAIDs) inhibit the COX activities of both PGHS-1 and PGHS-2 whereas COX-2 inhibitors called coxibs are more selective for huPGHS-2 (Grosser et al., 2006) . nsNSAIDs and coxibs fall into three general categories based on their mechanisms of action, and their mechanisms are related in part to the way in which they MOL 63115 8
The presence of the mutations was confirmed by DNA sequencing. The primers used to prepare the S530A mutation were as follows: ggAgCACCATTCgCCTTgAAAggACTTATg and CATAAgTCCTTTCAAggCgAATggTgCTCC.
Using the Life Technologies (Grand Island, NY) Bac-to Bac expression system protocol, bacmid DNA was generated and used to transfect Sf21 insect cells. Virus was harvested and used to infect cultures of sf21 cells. After 72-96 h of infection, the cells were collected and used to purify protein.
Sf21 cell pellets were resuspended in Ni-solubilization buffer (20 mM TrisHCl, pH 7.4
and 100 mM NaCl) containing Complete EDTA -free Protease Inhibitor (Roche). The enzyme was solubilized with C 10 E 6 (0.8% vol/vol), and insoluble material was removed by centrifugation. Enzymes were purified from the solubilized supernatant using a combinantion of chromatography on fast-flow Ni-NTA resin (Qiagen) and FLAG-affinity resin (Sigma) essentially as reported previously (Liu et al., 2007; Yuan et al., 2009) . Purified protein at a concentration of about 100 ȝg/ml was concentrated to 0.5-4 mg/ml using a Millipore centrifugal filter with a cutoff molecular weight of 50,000.
Radio-Thin Layer Chromatography Of Prostaglandin Products. Thin layer chromatography was used to separate the products formed from [1-14 C]-AA or [1-14 C]-EPA by native huPGHS-2 or S530A/S530A huPGHS-2 before and after incubation with 500 μM aspirin for 1 hour at 37 o C. The reactions were performed in standard assay buffer containing 0.1 M TrisHCl, pH 8.0 containing 1 mM phenol and 5 mM hematin and allowed to proceed for 40 sec at 37 o C with or without 12.5 mM diclofenac. The reactions were quenched with stop buffer consisting of ethyl ether/methanol/0.2 M citric acid; 30/4/1. The resultant solutions were centrifuged at 4 °C for 10 min at 1000 x g. An aliquot of the organic layer (100 ȝl) was subjected This article has not been copyedited and formatted. The final version may differ from this version. to thin layer chromatography on a silica gel G plate in ethyl acetate/2,2,4-trimethylpentane/acetic acid/water (110:50:20:100). After exposing the thin layer plates to x-ray film, the films were scanned and the density of the radioactive bands quantified with the NIH ImageJ program (ver.
1.38x). The product compositions were calculated based on the percentage of the band intensity (e.g. measuring those bands that co-chromatographed with AA, 15-HETE or PGH 2 ).
Cyclooxygenase Assays. COX assays were performed as detailed previously (Liu et al., 2007) . COX reaction mixtures typically contained 3 ml of 0.1 M TrisHCl, pH 8.0, 100 μM arachidonic acid, 1 mM phenol, and 5 μM hematin equilibrated in a glass chamber at 37 °C.
Reactions were initiated by adding enzyme to the assay chamber. A Yellow Springs Instruments
Model 53 Oxygen monitor was used to monitor O 2 consumption by native or mutant PGHSs with kinetic traces recorded using (DaisyTec) software. The rates reported are maximum rates occurring after a short lag phase. One unit of COX activity is defined as 1 μmol of O 2 consumed/min at 37 °C in the assay mixture. Igor Pro version 6.0 was used for graphing K m and V max . The errors are reported as standard deviations from multiple kinetic trials.
Quantitation of Aspirin Acetylation. Native huPGHS-2 and S530A huPGHS-2 variants were incubated with 0.5, 1 or 2 mM [1-14 C]-acetylsalicylate for different times at either room temperature (ca. 24°) or 37° (Bala et al., 2008) . The resulting mixture was treated with cold 10 % TCA and filtered through 1 μM pore-sized filters under vacuum. The filters were washed with 5 ml of cold TCA containing 8 mM unlabeled ASA. After washing, the filters were transferred to scintillation vials and allowed to equilibrate with the scintillation fluid for at least 24 hr.
Radioactivity was quantified by liquid scintillation counting.
LC-MS/MS Analysis of EPA and DHA Reaction Products of PGHS-2. Mass spectrometric analysis was performed with a Surveyor HPLC (ThermoFinnigan, San Jose, CA) interfaced directly to the electrospray ionization source of an LTQ linear ion trap mass spectrometer (ThermoFinnigan, San Jose, CA). Sample mixtures were separated using a Gemini C6-Phenyl analytical column (150x2.00 mm, 3 micron particles; Phenomenex, Torrance, CA) with a binary gradient at a flow rate of 0.22 ml/min. Solvent A was 10 mM ammonium acetate, pH 8.5 and Solvent B was methanol. A linear gradient from 50% Solvent B to 100% Solvent B over 50 min followed by a hold at 100% B for 10 min was used to elute compounds of interest.
The column was maintained at 50 o C and the sample compartment was cooled to 4 o C. Negative ions were generated in the ESI source using nitrogen as the sheath and auxillary gas under the following conditions: spray voltage, 3.0 kV; tube lens, -52 V; sheath gas, 30 psi; auxilliary gas, 5 units; capillary temperature, 300 o C. For identification of the reaction products, the mass spectrometer was set up to collect survey data in full scan mode from m/z 150-1000, and four independent MS2 scans based on a mass list of precursor ions for the substrates and predicted monohydroxy reaction products. The normalized collision energy was set to 26%. An additional scan function was added to the method for semi-quantitative analysis. Data were collected using selected ion monitoring of the [M-H] -ions of the substrates, the products, and the internal standard (d8-15-HETE). Xcalibur software (v 1.4, ThermoFinnigan, San Jose, CA) was used for instrument control and data analysis.
This article has not been copyedited and formatted. The final version may differ from this version. Effect of Diclofenac on huPGHS-2. Ser-530 but not Arg-120 is important for inhibition of the COX activity of murine PGHS-2 by diclofenac (Rowlinson et al., 2003) . Consistent with this, we found that diclofenac was an ineffective inhibitor of S530A/S530A huPGHS-2 but completely inhibited native huPGHS-2 (Table 1) . Diclofenac caused a time-dependent inhibition of native huPGHS-2 (Table 1 and Fig. 1 ). As shown in Fig. 1A , the activity of enzyme that had been pretreated with diclofenac was not immediately regained-as it would be for a freely reversible inhibitor-when the enzyme was assayed in the presence of a non-inhibitory concentration of diclofenac. This behavior is similar to that observed with indomethacin ( Fig.   1A ), which has been well-documented to be a time-dependent COX inhibitor. When titrated with diclofenac, maximal inhibition of native huPGHS-2 occurred at a ratio of one diclofenac molecule per molecule of huPGHS-2 dimer (Fig. 1B) . Thus, binding of diclofenac to a single monomer of huPGHS-2 inhibits the activity of both monomers. Comparison of the results obtained with native huPGHS-2 vs. mutant huPGHS-2 imply that Ser-530 needs to be present in at least a single monomer for time-dependent inhibition by diclofenac to occur (Table 1) . Ser530
is not required for inhibition by indomethacin, fluribiprofen or meclofenamate, which are also maximally effective at one inhibitor molecule per dimer (DeWitt et al., 1990; Kulmacz and Lands, 1985; Prusakiewicz et al., 2009; Yuan et al., 2006; Yuan et al., 2009) and mediate an inhibition requiring interaction with Arg-120 (Bhattacharyya et al., 1996; Rieke et al., 1999; Rowlinson et al., 2003; Yuan et al., 2006) but not Ser-530 (Rowlinson et al., 2003) . formed by aspirin-treated native huPGHS-2 at significantly greater levels and in higher proportions relative to PGH 2 than by untreated enzyme. Importantly, diclofenac inhibits PGH 2 formation by acetylated huPGHS-2 to a much greater extent than 15-HETE production. Based on studies with S530A PGHS-2, we assume that diclofenac binds to the non-acetylated monomer having an unaltered Ser-530 to block PGH 2 formation but not to the acetylated monomer to block 15-HETE formation. This implies that the acetylated monomer forms 15-HETE and the non-acetylated monomer forms primarily PGH 2 .
Oxygenation of EPA by huPGHS-2. EPA and DHA are poorer substrates than AA for huPGHS-2 (Liu et al., 2006; Wada et al., 2007; Yuan et al., 2009) . With saturating concentrations of fatty acid substrate (100 PM), the relative COX activities of huPGHS-2 with AA, EPA and DHA were 100%, 45% and 15%, respectively (Table 2) . It should be noted that these values are normalized rates of formation of oxygenated fatty acids corrected for differences in rates of oxygen consumption that are intrinsically higher with fatty acids such as AA that are bis-oxygenated. Although there is some information in the literature (Serhan et al., 2002) , the details concerning the nature and ratios of the products formed from EPA and DHA by highly purified huPGHS-2 have not been reported previously. We found that huPGHS-2 converts 100
This article has not been copyedited and formatted. The final version may differ from this version. (Tables 2 and 3 , Fig. 3 ). The formation of 11-HEPE was confirmed by matching the retention time and MS/MS spectrum with an authentic 11-HEPE standard. No 14-HEPE standard is commercially available.
The conclusion that the second monohydroxy acid is 14-HEPE is based on the information summarized in Table 3 . The MS/MS spectrum is consistent with the fragments predicted for 14-HEPE, and reduction of the carbon-carbon double bonds of the unknown acid (predicted to be 14-HEPE) yields a product with a 10 Da increase in molecular weight and an MS/MS spectrum expected for 14-hydroxyeicosanoic acid. The only straightforward mechanism for the formation of 14-HEPE would seem to be abstraction of the omega-5 hydrogen from EPA; however, we are unaware of a precedent for this for native PGHSs Aspirin-acetylated huPGHS-2 converted 100 PM EPA to a mixture of four different hydroxy acids (60% of the products) and PGH 3 (40% of the products) (Fig. 3) . A minor product is 18-HEPE, which represents 7% of the total oxygenated products. Oxygenated products were not detected when [1-14 C]-EPA (100 PM) was incubated with aspirin-acetylated huPGHS-2 in the presence of diclofenac (12.5 PM) (data not shown). This is unlike what is seen with AA as a substrate (Fig. 2C) .
In experiments similar to those reported in Table 2 , we analyzed the efficiency of oxygenation of EPA by native huPGHS-2 and aspirin-treated huPGHS-2 at a concentration (5 PM) nearer to that likely to be physiologically relevant (Table 4) . We also tested the effect of 25
PM palmitic acid on EPA oxygenation because palmitic acid is the most abundant free fatty acid (Table 1; (Yuan et al., 2009)). Palmitic acid had little or no effect on the rate of EPA oxygenation or the pattern of products formed by native huPGHS-2; in the presence of palmitic acid is oxygenated at 25% of the rate of AA. Aspirin-treated huPGHS-2 has only 35% of native huPGHS-2 activity with 5 PM EPA. The product profile is shifted somewhat so that more monohydroxy fatty acids are formed, but the effect of aspirin to increase monohydroxy acid formation from EPA is much
less pronounced than what is observed with AA. 18-HEPE is detectable as one of the products of EPA but comprises only 2% of the total products with 5 PM EPA ( Table 4 ).
Oxygenation of DHA by huPGHS-2. The specific activity of highly purified huPGHS-2 with 100 PM DHA is 15% of the specific activity observed with 100 PM AA ( Table 2) .
Following incubation of huPGHS-2 or aspirin-acetylated huPGHS-2 with DHA, the only products visualized following thin-layer chromatography co-chromatographed with authentic 13-hydroxydocosahexaenoic acid (HDHA) and 17-hydroxydocosahexaenoic acid (17-HDHA) standards, and the latter two hydroxydocosahexaenoic acid standards co-chromatographed in the thin layer chromatography system used in our experiments (data not shown). We subsequently analyzed the products by LC-MS/MS (Tables 2 and 4 and Fig. 4) . Consistent with what has been reported (Serhan et al., 2002) , highly purified huPGHS-2 converts DHA exclusively to 13-hydroxydocosahexaenoic acid (HDHA). The identity of 13-hydroxy-docosahexaenoic acid was confirmed by matching the retention time and MS/MS spectrum with that of a 13-HDHA standard (Fig. 4) . Aspirin-acetylated huPGHS-2 has less than one third of the activity of native huPGHS-2 with 100 PM DHA, and forms a mixture of 13-HDHA (~25%) and 17-HDHA (~75%). As was observed using EPA as the substrate, diclofenac (12.5 PM) completely inhibited the oxygenation of DHA (100 PM) by aspirin-acetylated huPGHS-2.
This article has not been copyedited and formatted. The final version may differ from this version. Experiments were also performed with 5 PM DHA in the presence and absence of palmitic acid (Table 4) . The results are qualitatively and quantitatively similar to those seen with 100 PM DHA ( Table 2 ). The relative amounts of 13-HDHA vs. 17-HDHA formed from 5 PM DHA by aspirin-treated huPGHS-2 was unaffected by the presence of 5 PM AA. There was also no appreciable effect of 5 PM DHA on the formation of AA-derived products (data not shown).
The latter results are consistent with previous measurements of rates of O 2 consumption when
DHA and AA are co-incubated with huPGHS-2 (Yuan et al., 2009).
This article has not been copyedited and formatted. The final version may differ from this version. Our results demonstrate that only a single monomer of PGHS-2 is acetylated by aspirin but that the outcome is somewhat more complex than seen with PGHS-1. The enzyme retains a significantly compromised ability to form PGH 2 , and additionally, produces an alternative product 15-HETE. The fact that PGH 2 formation is more than 80% inhibited by diclofenac while the formation of 15-HETE is reduced by only 20% suggests that diclofenac is binding to the nonacetylated monomer of aspirin-treated PGHS-2 and that this monomer be the one that forms PGH 2 while the acetylated monomer forms primarily 15R-HETE. Thus, the effect of aspirin on PGHS-2 is an incomplete allosteric inhibition effect compared to that seen with PGHS-1. Our ability to draw these conclusions depends on the use of diclofenac, which is an unusual antiinflammatory drug that functions by interacting with Ser530 and not Arg120 (Rowlinson et al., 2003) .
Diclofenac completely inhibited the oxygenation of EPA and DHA by aspirin-acetylated huPGHS-2. This suggests that all of the products derived from EPA and DHA are formed by the non-acetylated subunit; however, we cannot exclude the possibility that diclofenac also indirectly interferes with the binding of EPA and DHA to the aspirin-acetylated monomer and inhibits EPA and DHA oxygenation in both monomers. In the context of differential usage of AA, EPA and DHA by the acetylated vs. non-acetylated monomers, the differential effect of palmitic acid may be relevant. Palmitic acid had little or no effect on the pattern of products formed from EPA or DHA by aspirin-acetylated PGHS-2 but had a significant effect on the product profile with AA.
With AA and palmitic acid and aspirin-treated huPGHS-2, there was a relative increase in PGH 2
This article has not been copyedited and formatted. The final version may differ from this version. at the expense of 15-HETE formation. We speculate that palmitic acid preferentially binds the acetylated subunit and interferes with events occurring in that subunit.
Resolvin E1 (RvE1) has potent biological activity in the resolution of inflammation (Serhan et al., 2008) . It can be formed in complex tissue systems primed with aspirin pretreatment and exogenous EPA (Arita et al., 2005; Serhan et al., 2000) . Moreover, RvE1 can be detected in plasma at a level of up to 1 nM in individuals given a bolus of EPA and treated with aspirin (Arita et al., 2005) . A minimal concentration of 1 nM seems to be required for bioactivity (Arita et al., 2005) .
The proposed pathway for RvE1 formation involves an initial production of 18R-HEPE via aspirin-acetylated PGHS-2 and subsequent further oxygenation. Although 18R-HEPE was reportedly formed by microsomes containing recombinant PGHS-2 (Serhan et al., 2000) , in our hands, purified recombinant huPGHS-2 did not form this product at saturating concentrations of EPA (100 PM). In agreement with previous studies, 18R-HEPE was formed by purified huPGHS-2 following aspirin treatment. However, 18R-HEPE was the least abundant of five products formed from EPA, and aspirin-acetylated huPGHS-2 has 35% of the oxygenase activity of native huPGHS-2 with EPA. With concentrations of EPA (5 PM) approaching but likely to be even higher than those available under physiological conditions, 18R-HEPE represented only 2% of the products formed from EPA by aspirin-treated, purified huPGHS-2. 18-HEPE formation by aspirin-treated huPGHS-2 from EPA plus palmitic acid occurs at less than 0.25% of the rate of PGH 2 formation from AA plus palmitic acid by native huPGHS-2. In short, while RvE1 is biologically active, we suspect that it could be formed via huPGHS-2 only in quite low abundance and only in highly unusual biological settings.
This article has not been copyedited and formatted. The final version may differ from this version. 17R-RvD1 is reportedly formed from DHA, the first step being the conversion of DHA to 17R-HDHA (Serhan et al., 2008; Serhan et al., 2002) . Again, using the extreme comparison of the relative rates of PGH 2 formation by native huPGHS-2 in the presence of palmitic acid vs. 17-HDHA formation from DHA in the presence of palmitic acid by aspirin-treated huPGHS-2
indicates that 17-HDHA synthesis by aspirin-treated huPGHS-2 occurs maximally at ~5% of the rate of PGH 2 synthesis by native huPGHS-2. Aspirin-acetylated huPGHS-2 showed no obvious preference for AA vs. DHA when these fatty acids were tested together at 5 PM each. Purified huPGHS-2 (2 μM) was pretreated with (a,b and c) no inhibitor for 10 minutes at 37 º C or (d) 12 μM diclofenac for 10 minutes at 37 º C or (e) 100 PM indomethacin for 5 minutes at 37 º C. No inhibitor was added to the O 2 electrode assay chamber when Sample (a) was assayed.
Diclofenac (0.16 PM) was included in the assay chamber when sample (b) was assayed; sample (b) served as the negative control for sample (d). Indomethacin (1.3 PM) was included in the assay chamber when sample (c) was assayed; sample (c) served as the negative control for sample (e). Dilution of the aliquot of sample (d) yielded a final concentration of 0.16 PM diclofenac in the assay chamber, and no additional diclofenac was added to this assay chamber.
Dilution of the aliquot of sample (e) yielded a final concentration of 1.3 PM indomethacin in the assay chamber, and no additional indomethacin was added to this assay chamber. Assays were performed at 37 º C in 3 ml of 0.1 M TrisHCl, pH 8.0 containing 100 PM arachidonic acid, 1 mM phenol and 1 PM hematin. (B) Purified huPGHS-2 (2.1 μM) was pretreated with the indicated concentrations of diclofenac at 37 º C for 10 min and then assayed for COX activity with 100 μM AA essentially as described above. Error bars show standard deviations from multiple kinetic trials. in the presence and absence of 12.5 PM diclofenac (Diclo) as described in Materials and
Methods. TLC was used to separate the endoperoxide (PGH 2 ) and monohydroxy acid products, mainly 15-HETE. To perform the assays [1-14 C] AA (100 PM) was mixed with ~ 9 μg of native huPGHS-2 in an assay volume of 0.10 ml, and the reactions were allowed to proceed for 40 sec.
The reactions were stopped, and the products were extracted, separated and visualized by autoradiography as shown. The thin layer plates were subsequently scraped and the amount of radioactivity co-chromatographing with AA, PGH 2 and 15-HETE standards was determined by scintillation counting. Numbers obtained from scintillation counting were used to calculate the percentage of total radioactivity found in each product. The experiment was performed three times with consistent results. 
